Phase 3 Readout

TLX: Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific

Name: Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific
Start: 2027-04-01
End: 2027-04-01

April 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: April 1, 2027
Company: Telix Pharmaceuticals Limited (TLX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific

April 1, 2027

TLX overview →

Company: Telix Pharmaceuticals Limited (TLX)
Indication: Prostate Cancer; Prostate Biopsy; Prostatic Neoplasm